Table 2.
Subtype | Prevalence | Features |
---|---|---|
CMS1 (Microsatellite instability immune) | 14% | Hypermutated Microsatellite unstable Strong immune activation |
CMS2 (Canonical) | 37% | Epithelial WNT and MYC signaling activation |
CMS3 (Metabolic) | 13% | Epithelial Metabolic dysregulation |
CMS4 (Mesenchymal) | 23% | TGF-β activation Stromal invasion Angiogenesis |